In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae. / Antenucci, Fabio; Fougeroux, Cyrielle; Deeney, Alannah; Ørskov, Cathrine; Rycroft, Andrew; Holst, Peter Johannes; Bojesen, Anders Miki.

In: Veterinary Research, Vol. 49, No. 1, 4, 01.2018.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Antenucci, F, Fougeroux, C, Deeney, A, Ørskov, C, Rycroft, A, Holst, PJ & Bojesen, AM 2018, 'In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae', Veterinary Research, vol. 49, no. 1, 4. https://doi.org/10.1186/s13567-017-0502-x

APA

Antenucci, F., Fougeroux, C., Deeney, A., Ørskov, C., Rycroft, A., Holst, P. J., & Bojesen, A. M. (2018). In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae. Veterinary Research, 49(1), [4]. https://doi.org/10.1186/s13567-017-0502-x

Vancouver

Antenucci F, Fougeroux C, Deeney A, Ørskov C, Rycroft A, Holst PJ et al. In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae. Veterinary Research. 2018 Jan;49(1). 4. https://doi.org/10.1186/s13567-017-0502-x

Author

Antenucci, Fabio ; Fougeroux, Cyrielle ; Deeney, Alannah ; Ørskov, Cathrine ; Rycroft, Andrew ; Holst, Peter Johannes ; Bojesen, Anders Miki. / In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae. In: Veterinary Research. 2018 ; Vol. 49, No. 1.

Bibtex

@article{76d02b9819a54b6a86e88ebb6bc3e8e5,
title = "In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae",
abstract = "Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium that represents the main cause of porcine pleuropneumonia in pigs, causing significant economic losses to the livestock industry worldwide. A. pleuropneumoniae, as the majority of Gram-negative bacteria, excrete vesicles from its outer membrane (OM), accordingly defined as outer membrane vesicles (OMVs). Thanks to their antigenic similarity to the OM, OMVs have emerged as a promising tool in vaccinology. In this study we describe the in vivo testing of several vaccine prototypes for the prevention of infection by all known A. pleuropneumoniae serotypes. Previously identified vaccine candidates, the recombinant proteins ApfA and VacJ, administered individually or in various combinations with the OMVs, were employed as vaccination strategies. Our data show that the addition of the OMVs in the vaccine formulations significantly increased the specific IgG titer against both ApfA and VacJ in the immunized animals, confirming the previously postulated potential of the OMVs as adjuvant. Unfortunately, the antibody response raised did not translate into an effective protection against A. pleuropneumoniae infection, as none of the immunized groups following challenge showed a significantly lower degree of lesions than the controls. Interestingly, quite the opposite was true, as the animals with the highest IgG titers were also the ones bearing the most extensive lesions in their lungs. These results shed new light on A. pleuropneumoniae pathogenicity, suggesting that antibody-mediated cytotoxicity from the host immune response may play a central role in the development of the lesions typically associated with A. pleuropneumoniae infections.",
author = "Fabio Antenucci and Cyrielle Fougeroux and Alannah Deeney and Cathrine {\O}rskov and Andrew Rycroft and Holst, {Peter Johannes} and Bojesen, {Anders Miki}",
year = "2018",
month = "1",
doi = "10.1186/s13567-017-0502-x",
language = "English",
volume = "49",
journal = "Veterinary Research",
issn = "0928-4249",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae

AU - Antenucci, Fabio

AU - Fougeroux, Cyrielle

AU - Deeney, Alannah

AU - Ørskov, Cathrine

AU - Rycroft, Andrew

AU - Holst, Peter Johannes

AU - Bojesen, Anders Miki

PY - 2018/1

Y1 - 2018/1

N2 - Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium that represents the main cause of porcine pleuropneumonia in pigs, causing significant economic losses to the livestock industry worldwide. A. pleuropneumoniae, as the majority of Gram-negative bacteria, excrete vesicles from its outer membrane (OM), accordingly defined as outer membrane vesicles (OMVs). Thanks to their antigenic similarity to the OM, OMVs have emerged as a promising tool in vaccinology. In this study we describe the in vivo testing of several vaccine prototypes for the prevention of infection by all known A. pleuropneumoniae serotypes. Previously identified vaccine candidates, the recombinant proteins ApfA and VacJ, administered individually or in various combinations with the OMVs, were employed as vaccination strategies. Our data show that the addition of the OMVs in the vaccine formulations significantly increased the specific IgG titer against both ApfA and VacJ in the immunized animals, confirming the previously postulated potential of the OMVs as adjuvant. Unfortunately, the antibody response raised did not translate into an effective protection against A. pleuropneumoniae infection, as none of the immunized groups following challenge showed a significantly lower degree of lesions than the controls. Interestingly, quite the opposite was true, as the animals with the highest IgG titers were also the ones bearing the most extensive lesions in their lungs. These results shed new light on A. pleuropneumoniae pathogenicity, suggesting that antibody-mediated cytotoxicity from the host immune response may play a central role in the development of the lesions typically associated with A. pleuropneumoniae infections.

AB - Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium that represents the main cause of porcine pleuropneumonia in pigs, causing significant economic losses to the livestock industry worldwide. A. pleuropneumoniae, as the majority of Gram-negative bacteria, excrete vesicles from its outer membrane (OM), accordingly defined as outer membrane vesicles (OMVs). Thanks to their antigenic similarity to the OM, OMVs have emerged as a promising tool in vaccinology. In this study we describe the in vivo testing of several vaccine prototypes for the prevention of infection by all known A. pleuropneumoniae serotypes. Previously identified vaccine candidates, the recombinant proteins ApfA and VacJ, administered individually or in various combinations with the OMVs, were employed as vaccination strategies. Our data show that the addition of the OMVs in the vaccine formulations significantly increased the specific IgG titer against both ApfA and VacJ in the immunized animals, confirming the previously postulated potential of the OMVs as adjuvant. Unfortunately, the antibody response raised did not translate into an effective protection against A. pleuropneumoniae infection, as none of the immunized groups following challenge showed a significantly lower degree of lesions than the controls. Interestingly, quite the opposite was true, as the animals with the highest IgG titers were also the ones bearing the most extensive lesions in their lungs. These results shed new light on A. pleuropneumoniae pathogenicity, suggesting that antibody-mediated cytotoxicity from the host immune response may play a central role in the development of the lesions typically associated with A. pleuropneumoniae infections.

U2 - 10.1186/s13567-017-0502-x

DO - 10.1186/s13567-017-0502-x

M3 - Journal article

C2 - 29316978

AN - SCOPUS:85040335280

VL - 49

JO - Veterinary Research

JF - Veterinary Research

SN - 0928-4249

IS - 1

M1 - 4

ER -

ID: 188635829